Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsMedica Hemophilia Prior Auth Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentMedicaPolicy N/A

    Hemophilia Product Prior Authorization Form - Coverage Criteria

    Customize your policy alerts

    Sign up for all Medica policy alerts

    Know when Medica releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This form governs prior authorization data collection for coverage of hemophilia and related coagulation factor products for Medica members; it affects prescribing providers, dispensing pharmacies, and reviewers assessing medical necessity.

    Policy Summary
    PayerMedica
    PolicyHemophilia Product Prior Authorization Form - Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit completed Hemophilia Product Prior Authorization Form with clinical information, dosing requested, and supporting labs/notes via fax or phone as provided on the form.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    9document chunks
    multiplecovered diagnoses listed
    labs & history

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    clinical docs requested

    Coverage Criteria and Documentation Requirements

    Authorization data required to establish medical necessity

    Covered when ALL of the following documentation elements are provided as applicable:

    required_fields: Completed patient, provider, and insurance information (demographics, prescriber, dispensing pharmacy, and insurance ID).

    Chunks: 1-4

    diagnosis_and_severity: Primary diagnosis selected from listed disorders and an ICD-10 code provided; severity of disease indicated (mild/moderate/severe).

    Chunk: 7

    treatment_intent_and_dosing: Product name, dose (IU), number of doses requested, total IU requested, dosing instructions, and type of use (episodic, prophylaxis, acute bleed, dental/surgical prophylaxis) provided; place of administration indicated.

    Chunk: 7

    laboratory_confirmation: Documentation of diagnosis by blood coagulation testing and baseline factor level with date and desired target factor level attached.

    Chunks: 7,8

    inhibitor_information: Inhibitor status provided and inhibitor test documentation attached if positive; prior ITI history and response provided if applicable.

    Chunk: 8

    bleeding_history: Number and location of bleeds in past 12 months and for acute episodes provide location, type, dates, doses used, and total amount used.

    Chunk: 9

    prior_therapy_trials: For VWD: desmopressin trial or documented contraindication; For Glanzmann's: platelet transfusion trial and response; document prior factor products and reason for switching.

    Chunk: 8

    The form does not specify explicit coverage exclusions; however, it requires documentation of prior standard therapies or documented contraindications where applicable. For example, the form requests prior trials of desmopressin for von Willebrand disease and platelet transfusions for Glanzmann's Thrombasthenia or a documented contraindication to those therapies when a trial was not performed. Providers should attach dates and responses to prior therapy trials when applicable to support medical necessity.

    The form must be completed in its entirety and faxed with relevant progress notes, bleeding diaries, and all laboratory results as instructed. The document does not enumerate specific not medically necessary conditions; however, incomplete or missing required documentation may result in denial of the prior authorization. Ensure all required fields and attachments are provided to avoid processing delays.

    Diagnosis and Coding Details

    Primary Diagnosis (ICD-10)ICD-10
    Congenital Hemophilia ACongenital Factor VIII Deficiency
    Acquired Hemophilia AAquired Factor VIII Deficiency
    Hemophilia BCongenital Factor IX Deficiency
    von Willebrand Disease
    Congenital Factor XIII Deficiency
    Congenital Factor XIII A-subunit Deficiency
    Hereditary Factor X Deficiency
    Congenital Factor VII Deficiency
    Glanzmann's Thrombasthenia
    ICD 10 CodeICD 10 Code (space provided on form for specific code)
    Exposure days threshold
    Exposure days threshold< 50 exposure days
    Field on formSeverity of Disease and treatment history requested to determine exposure days relevance
    UseApplied to differentiate treatment-naïve vs treatment-experienced patients for authorization considerations

    Submission Instructions and Required Provider Steps

    Prior Authorization

    Form submission requirement

    Submit the completed Hemophilia Product Prior Authorization Form along with all requested clinical documentation. Fax materials to 1-888-656-0841 or call 1-800-424-7892. All lab results and attachments must be included with the initial submission to avoid delay.

    • Hemophilia Product Prior Authorization Form (fully completed)
    • Progress notes and bleeding diaries
    • All relevant lab results (including baseline factor levels and dates)
    • Inhibitor testing results (e.g., Bethesda assay) when applicable
    • Pharmacokinetic (PK) test results, if performed
    • Documentation of prior factor products and reasons for switching
    • Immune Tolerance Induction (ITI) history and response, if applicable
    • For Glanzmann's Thrombasthenia: documentation of platelet transfusion trial and response
    • For von Willebrand Disease: documentation of desmopressin trial or contraindication explanation

    Information Required for Initial Authorization or New Product Starts

    Initial authorization documentation — information requested to support initiation or new product authorization

    Information requested to support initiation or new product authorization includes:

    baseline_labs: Baseline factor level, date of level, and desired target factor level; documentation of diagnosis by coagulation testing.

    Chunks: 7,8

    inhibitor_and_prior_trials: Inhibitor status and Bethesda assay results if positive; prior Immune Tolerance Induction (ITI) history with dates, duration, and response when applicable.

    Chunk: 8

    treatment_history_and_switching: History of prior factor products, whether patient was treatment-naïve or treatment-experienced, and reason for product switching if applicable.

    Chunk: 7

    Step Therapy / Prior Trial Requirements

    RequirementDocumentation to provide
    Prior therapy trial for von Willebrand Disease (VWD)
    Documentation of desmopressin trial or statement of contraindication (include reason if contraindicated)
    Prior therapy trial for Glanzmann's Thrombasthenia
    Documentation of platelet transfusion trial and patient response (dates and outcomes)
    Prior factor product use (minimally treated patients)
    For patients with < 50 exposure days, frequency of planned inhibitor testing and attached testing schedule/results
    Immune Tolerance Induction (ITI) history
    If ITI performed: dates, duration, and patient response

    Quantity and Dosing Information

    unspecified (product name provided on form) — dosing and IU required
    Required dose detailsNumber of doses requested must be provided on the form
    Required potency detailsTotal dose requested (IU) / Total units on hand (IU) must be provided
    Supporting verificationDate verified for medication on hand should be recorded
    Context fieldsDose (IU) and dosing instructions fields are present to support the requested quantity

    Place of Administration

    Note

    Specify place of administration

    Indicate the place of administration on the form by selecting one of the provided options (home infusion, outpatient hemophilia treatment center, outpatient hospital, provider's office, or self-administration).

    Disease Severity Definitions

    Severity of Disease (factor level categories)
    Mild disease6%–25% factor level
    Moderate disease1%–5% factor level
    Severe disease< 1% factor level

    Background and Purpose

    This Hemophilia Product Prior Authorization Form is used to document the member’s diagnosis, disease severity, bleeding history, and laboratory confirmation needed to support coverage of factor and related hemostatic products. The form collects severity of disease (Mild: 6%–25%, Moderate: 1%–5%, Severe: <1%), baseline and target factor levels with dates, inhibitor status, number and location of bleeds over the prior 12 months, intended type of use (episodic, prophylaxis, acute bleed, dental/surgical prophylaxis), and the place of administration (home infusion, HTC, outpatient hospital, or office).

    Policy Summary
    PayerMedica
    PolicyHemophilia Product Prior Authorization Form - Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit completed Hemophilia Product Prior Authorization Form with clinical information, dosing requested, and supporting labs/notes via fax or phone as provided on the form.
    SourceLink
    On This Page
    Coverage Criteria and Documentation RequirementsDiagnosis and Coding DetailsSubmission Instructions and Required Provider StepsInformation Required for Initial Authorization or New Product StartsStep Therapy / Prior Trial RequirementsQuantity and Dosing InformationPlace of AdministrationDisease Severity DefinitionsBackground and Purpose
    Documentation Required

    Prior therapy documentation

    Provide clear documentation of prior therapies or trials when requested. Include dates, doses, responses, and reasons therapy was discontinued or switched. This is required for evaluation of medical necessity.

    • Record of prior factor products used, dates and reason for switching
    • Desmopressin trial documentation for VWD patients (or documented contraindication and reason)
    • Platelet transfusion trial documentation for Glanzmann's Thrombasthenia (dates and response)
    • ITI treatment history (dates, duration, and patient response)
    Documentation Required

    Required attachments

    Required attachments must be included with the prior authorization submission. Failure to attach the items below may result in denial or delay of the request.

    • Progress notes and bleeding diaries covering relevant timeframe
    • All lab results including baseline factor level and date
    • Inhibitor testing results (e.g., Bethesda assay) when indicated
    • PK testing results, if available
    • Completed dosing information: dose (IU), number of doses requested, total IU, and dosing instructions
    • Documentation of treatment status (treatment-naïve vs experienced) and prior product use
    • Procedure dates for surgical or dental prophylaxis requests
    • Place of administration and type of use (episodic, prophylaxis, acute bleed)
    Denial Risk

    Incomplete submission risk

    Incomplete submissions — missing the completed form or any supporting documentation listed above — risk denial or processing delays. Ensure all checkboxes, clinical fields (e.g., severity, factor levels), and attachments are provided on initial submission.

    • Fax complete packet to 1-888-656-0841 or call 1-800-424-7892 for questions
    • All lab results must be faxed with the submission
    • Retrospective requests should clearly indicate retrospective status and include full clinical justification
    dosing_and_site_of_care: Requested dose (IU), number of doses, total IU requested, dosing instructions, type of use (episodic, prophylaxis, acute bleed, dental/surgical/surgical prophylaxis) and place of administration indicated (home, HTC, outpatient hospital, office, self-administration).

    Chunk: 7

    pk_and_monitoring: If performed, pharmacokinetics (PK) test results attached and plan for inhibitor testing for minimally treated patients (< 50 exposure days) documented.< 50 exposure days

    Chunk: 8

    acute_bleed_details: For acute bleeding episodes provide location, type (minor/moderate/major), start and end dates, number of doses used, dose (IU) and total amount used (IU).

    Chunk: 9